collection
MENU ▼
Read by QxMD icon Read
search

Rheum

shared collection
7 papers 25 to 100 followers
By Ana Monteiro Md/phd student
https://www.readbyqxmd.com/read/23852763/non-viral-opportunistic-infections-in-new-users-of-tumour-necrosis-factor-inhibitor-therapy-results-of-the-safety-assessment-of-biologic-therapy-saber-study
#1
John W Baddley, Kevin L Winthrop, Lang Chen, Liyan Liu, Carlos G Grijalva, Elizabeth Delzell, Timothy Beukelman, Nivedita M Patkar, Fenglong Xie, Kenneth G Saag, Lisa J Herrinton, Daniel H Solomon, James D Lewis, Jeffrey R Curtis
OBJECTIVES: To determine among patients with autoimmune diseases in the USA whether the risk of non-viral opportunistic infections (OI) was increased among new users of tumour necrosis factor α inhibitors (TNFI), when compared to users of non-biological agents used for active disease. METHODS: We identified new users of TNFI among cohorts of rheumatoid arthritis (RA), inflammatory bowel disease and psoriasis-psoriatic arthritis-ankylosing spondylitis patients during 1998-2007 using combined data from Kaiser Permanente Northern California, two pharmaceutical assistance programmes for the elderly, Tennessee Medicaid and US Medicaid/Medicare programmes...
November 2014: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/24979462/in-the-clinic-osteoarthritis
#2
REVIEW
Allan C Gelber
No abstract text is available yet for this article.
July 1, 2014: Annals of Internal Medicine
https://www.readbyqxmd.com/read/25193804/anti-nucleosome-antibodies-outperform-traditional-biomarkers-as-longitudinal-indicators-of-disease-activity-in-systemic-lupus-erythematosus
#3
COMPARATIVE STUDY
Timothy Li, Stephenie D Prokopec, Stacey Morrison, Wendy Lou, Heather Reich, Dafna Gladman, Murray Urowitz, James Scholey, Paul R Fortin, Paul C Boutros, Joan Wither, Carolina Landolt-Marticorena
OBJECTIVE: The aim of this study was to determine whether anti-nucleosome antibodies function as activity-specific biomarkers in SLE. METHODS: Fifty-one patients were recruited and followed prospectively with periodic clinical and biochemical assessments over a 14-month period. Disease activity was determined by the SLEDAI-2K. Anti-nucleosome antibody levels were measured by an ELISA and its utility as an activity-specific biomarker as compared with that of anti-dsDNA antibodies and C3 was assessed both at baseline and in longitudinal analysis...
March 2015: Rheumatology
https://www.readbyqxmd.com/read/24092418/classification-criteria-for-sjogren-s-syndrome-nothing-ever-stands-still
#4
EDITORIAL
Simon J Bowman, Robert I Fox
No abstract text is available yet for this article.
January 2014: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/21051743/updates-on-the-treatment-of-lupus-nephritis
#5
REVIEW
Andrew S Bomback, Gerald B Appel
The treatment of lupus nephritis has changed significantly over the past decade in large part because of data from well-conducted randomized clinical trials. The concept of two phases of therapy-induction and maintenance-is widely accepted. The histopathologic classification of lupus nephritis continues to guide therapy, and treatment for all major classes of lupus nephritis has seen some shift in management during this time. New regimens using lower doses and shorter treatment durations of intravenous cyclophosphamide have been advanced to reduce toxicity without sacrificing efficacy of therapy...
December 2010: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/19587374/how-i-treat-the-antiphospholipid-syndrome
#6
REVIEW
Bill Giannakopoulos, Steven A Krilis
This article discusses how we approach medical decision making in the treatment of the various facets of the antiphospholipid syndrome (APS), including secondary prophylaxis in the setting of venous and arterial thrombosis, as well as treatment for the prevention of recurrent miscarriages and fetal death. The role of primary thromboprophylaxis is also discussed in depth. Great emphasis is given to incorporating the most up-to-date and relevant evidence base both from the APS literature, and from large, recent, randomized controlled trials (RCTs) of primary and secondary thrombotic prophylaxis in the general population setting (ie, the population that has not been specifically investigated for APS)...
September 3, 2009: Blood
https://www.readbyqxmd.com/read/16275885/sildenafil-in-the-treatment-of-raynaud-s-phenomenon-resistant-to-vasodilatory-therapy
#7
Roland Fries, Kaveh Shariat, Hubertus von Wilmowsky, Michael Böhm
BACKGROUND: Vasodilatory therapy of Raynaud's phenomenon represents a difficult clinical problem because treatment often remains inefficient and may be not tolerated because of side effects. METHODS AND RESULTS: To investigate the effects of sildenafil on symptoms and capillary perfusion in patients with Raynaud's phenomenon, we performed a double-blinded, placebo-controlled, fixed-dose, crossover study in 16 patients with symptomatic secondary Raynaud's phenomenon resistant to vasodilatory therapy...
November 8, 2005: Circulation
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"